【24h】

Preparation of Jingzhiguanxin Monolithic Osmotic Pump Tablet

机译:净之冠心整体渗透泵片的制备

获取原文
获取原文并翻译 | 示例

摘要

With the development of modern pharmaceutics, various good prerequisites are supplied for controlled-release dosage forms of TCM. Osmotic pump controlled release preparation is one of the most ideal preparations in controlled-releasing effect and has achieved the world advanced level because of its many advantages. Jingzhiguanxin prescription is an effective TCMCR, with improving blood circle and clearing up silt in the body, composed of "danshen", "chishao", "chuanxiong", "honghua" and "jiangxiang". Most Chinese medicines are administered orally as decoctions or tablets in clinics, in which the composite formulae will isochronous release and produce a synergistic effect or antagonistic action. So it is not enough that only one maker compound is studied. In this paper, three maker compounds, which represent three main drugs made of Jingzhiguanxin prescription, were studied. It is expected that three maker compound could isochronous release and produced a synergistic effect or antagonistic action.
机译:随着现代药物的发展,为中药控释剂型提供了各种良好的先决条件。渗透泵控释制剂是控制释放效果最理想的制剂之一,由于其许多优点,已达到世界先进水平。精制冠心方是由丹参,赤chi,川xi,红花,降香组成的有效中药,具有改善血液循环,清除体内淤泥的作用。大多数中药在临床上以汤剂或片剂形式口服给药,其中的复合配方会等时释放,并产生协同作用或拮抗作用。因此仅研究一种制造化合物是不够的。本文研究了代表三种以治之冠心处方制成的主要药物的三种制造商化合物。预期三种制造者化合物可以同步释放并产生协同作用或拮抗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号